CD40L protects against mouse hepatitis virus-induced neuroinflammatory demyelination

PLoS Pathog. 2021 Dec 13;17(12):e1010059. doi: 10.1371/journal.ppat.1010059. eCollection 2021 Dec.

Abstract

Neurotropic mouse hepatitis virus (MHV-A59/RSA59) infection in mice induces acute neuroinflammation due to direct neural cell dystrophy, which proceeds with demyelination with or without axonal loss, the pathological hallmarks of human neurological disease, Multiple sclerosis (MS). Recent studies in the RSA59-induced neuroinflammation model of MS showed a protective role of CNS-infiltrating CD4+ T cells compared to their pathogenic role in the autoimmune model. The current study further investigated the molecular nexus between CD4+ T cell-expressed CD40Ligand and microglia/macrophage-expressed CD40 using CD40L-/- mice. Results demonstrate CD40L expression in the CNS is modulated upon RSA59 infection. We show evidence that CD40L-/- mice are more susceptible to RSA59 induced disease due to reduced microglia/macrophage activation and significantly dampened effector CD4+ T recruitment to the CNS on day 10 p.i. Additionally, CD40L-/- mice exhibited severe demyelination mediated by phagocytic microglia/macrophages, axonal loss, and persistent poliomyelitis during chronic infection, indicating CD40-CD40L as host-protective against RSA59-induced demyelination. This suggests a novel target in designing prophylaxis for virus-induced demyelination and axonal degeneration, in contrast to immunosuppression which holds only for autoimmune mechanisms of inflammatory demyelination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD4-Positive T-Lymphocytes
  • CD40 Ligand / immunology*
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / pathology
  • Mice
  • Murine hepatitis virus
  • Nervous System Autoimmune Disease, Experimental / immunology*
  • Nervous System Autoimmune Disease, Experimental / pathology
  • Nervous System Autoimmune Disease, Experimental / virology*

Substances

  • CD40 Ligand

Grants and funding

This work was supported by a Department of Biotechnology (DBT), India, research grant (BT/PR 20922/MED/122/37/2016). JDS received this grant. The Council of Scientific and Industrial Research (CSIR) India provided fellowships to F.S. and S.K.; the Ministry of Human Resource Development (MHRD), India provided fellowship to D.C; and the University Grants Commission (UGC), India, provided fellowship to M.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.